Pleurodynia Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Denmark, China, Norway - Size and Forecast 2024-2028

Pleurodynia Treatment Market Size 2024-2028 

The pleurodynia treatment market size is forecast to increase by USD 16.5 million and is estimated to grow at a CAGR of 3.28% between 2023 and 2028. The market is experiencing significant growth and transformation due to several key drivers. The increasing prevalence of viral infections and chronic diseases necessitates the continuous development of new drugs and treatments. In response, there is a surge in research and development (R&D) initiatives in the healthcare sector. Additionally, there is a growing emphasis on ensuring the proper use and distribution of drugs to maximize their effectiveness and minimize potential harm. This includes efforts to improve drug safety, reduce counterfeit drugs, and expand access to affordable medicines in underserved communities. The pharmaceutical industry's ability to innovate and adapt to these challenges will be crucial in improving global health outcomes and driving long-term growth.

What will be the Size of the Market During the Forecast Period?

For More Highlights About this Report, Request Free Sample

Market Dynamic and Customer Landscape

Pleurodynia, also known as Bornholm disease or epidemic myalgia, is a viral condition characterized by severe muscle pain, particularly in the abdomen and back. The primary cause of pleurodynia is the Coxsackievirus B. The healthcare system has been under pressure due to lockdown norms, social isolation, and the resulting increase in stress-related conditions like depression and anxiety. This has led to a significant increase in the number of patients seeking pleurodynia treatment. The pleurodynia treatment market is witnessing growth due to the development of innovative drugs and pain management therapies. Painkiller medications, such as analgesics and opioids, continue to dominate the market. However, the shift towards non-opioid medications is gaining momentum due to their safety profile and affordability. The prevalence of pleurodynia is high in populations with unhealthy lifestyles, making healthcare affordability a significant concern. The pleurodynia treatment market is expected to witness development activities, with several companies focusing on product pipeline analysis to meet the growing demand. Domestic markets are expected to be significant revenue pockets for players in the pleurodynia treatment market, making strategic decisions crucial for market success. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage. Thus, such factors are driving the growth of the market during the forecast period.

Key Market Driver

Growing prevalence of viral infections is notably driving market growth. Pleurodynia, also known as epidemic myalgia or Bernasconi-Civai disease, is a viral condition characterized by the sudden onset of chest or abdominal pain, fever, malaise, and headaches. This disease primarily affects older children and adults, with abdominal involvement more common in younger populations.

Moreover, The primary causative agents of pleurodynia are viruses, specifically Coxsackie B3 and B5. The global pleurodynia treatment market is undergoing significant changes due to technological advancements and increasing prevalence of the disease in both developed and emerging economies.

Significant Market Trends

Growing partnerships is the key trend in the market. The Market is witnessing significant collaborations between private manufacturers and public health organizations in developed and emerging economies. These partnerships aim to facilitate cost-effective research and development of vaccines and antiviral drugs for both current and future pandemics.

For instance, in November 2021, the State of Qatar and the World Health Organization (WHO) announced a partnership to address global health challenges jointly. Similarly, in June 2021, The US Department of Health and Human Services (HHS) initiated a public-private partnership, enabling venture capital investments. Thus, such trends will shape the growth of the market during the forecast period.

Major Market Challenge

Stringent regulatory guidelines is the major challenge that affects the growth of the market. The Market is subjected to rigorous pharmaceutical drug development and approval processes overseen by regulatory authorities worldwide. Safety, efficacy, pharmacological data, pharmacodynamic effects, and drug interactions are paramount considerations in this process. Failure to meet any of these criteria may result in a Complete Response Letter (CRL) or outright rejection from regulatory agencies. In such cases, drug applicants are obliged to provide supplementary data, often necessitating additional clinical trials, thereby increasing research and development expenditures.

Moreover, this stringent regulatory environment is a common thread in both developed and emerging economies. Technological changes, such as advanced analytics and automation, are transforming the drug development landscape, enabling faster and more efficient regulatory approvals. Hence, the above factors will impede the growth of the market during the forecast period

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Abbott Laboratories: The company offers pleurodynia treatment products such as BRUFEN®(Ibuprofen).

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• GlaxoSmithKline Plc
• Hudson Pharma
• Johnson and Johnson Services Inc.
• Merck and Co. Inc.
• Novartis AG
• Opsonin Pharma Ltd.
• Pfizer Inc.
• Reckitt Benckiser Group Plc
• Sanofi SA

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

By Therapy 

The painkillers segment is estimated to witness significant growth during the forecast period. Pleurodynia, also known as epidemic myalgia or Bornholm disease, is an illness characterized by flu-like symptoms and severe pain in the chest or abdomen. This condition is primarily caused by the Coxsackie B virus, although the Coxsackie A virus and certain echoviruses can also be responsible.

Get a glance at the market share of various regions Download the PDF Sample

The painkillers segment was the largest segment and valued at USD 56.30 million in 2018. The virus triggers inflammation, particularly in the muscles of the chest wall, leading to pain and discomfort. The healthcare system faces challenges in managing pleurodynia due to social isolation and psychological consequences such as depression and anxiety in patients. The prevalence of this disease varies in different populations, and its affordability can impact treatment options. While there is no specific treatment for pleurodynia, pain management therapies including painkiller medications like analgesics, opioids, and non-opioid medications can help alleviate symptoms. Hence, such factors are fuelling the growth of this segment during the forecast period.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 53% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The Pleurodynia treatment market encompasses various interventions for managing the symptoms and complications of Pleurodynia, a condition characterized by severe muscular pain, often caused by Coxsackievirus B, Coxsackievirus A, Echovirus, or Bornholm disease. The healthcare system plays a crucial role in diagnosing and treating affected patients, who may experience social isolation, depression, and anxiety due to the debilitating nature of the disease. Painkiller medications, such as analgesics and opioids, are commonly used for pain management. Hence, such factors are driving the market in North America during the forecast period.

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments

• Therapy Outlook
  • Painkillers
  • Immunoglobulin
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa

You may also interested in below market reports:

Thoracic Catheters Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast

Pulmonary Edema Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Canada - Size and Forecast

Thoracic Surgery Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, China, Japan - Size and Forecast

Market Analyst Overview

 Pleurodynia, also known as Bornholm disease or epidemic myalgia, is a viral condition characterized by severe muscle pain, particularly in the abdomen and back. Caused by Coxsackievirus B, this condition can lead to social isolation, depression, and anxiety due to the debilitating pain. The market landscape depends on the Unhealthy lifestyle, Epidemic pleurodynia, Prevalence of disease, Causes, Inflammation around the heart, Inflammation around the brain, Inflammation of the liver, Inflammation of the testicles, Chest pain, Benchmark analysis, Developed economies. The market caters to the needs of patients seeking relief from the symptoms. The market comprises painkiller medications, pain management therapies, and innovative drugs. Analgesics, including opioids and non-opioid medications, are commonly used for pain relief. However, the healthcare system's affordability and the prevalence of the disease in the population are significant factors influencing the market's growth. The market's development activities include product pipeline analysis, focusing on domestic revenue pockets and strategic decisions to cater to the growing demand. Complications from the disease, such as rapid heart rate, fever, cough, headache, sore throat, muscular aches, and pains, necessitate effective treatment. Other viruses, like Coxsackievirus A and Echovirus, can also cause pleurodynia-like symptoms. The market's growth is driven by the increasing prevalence of unhealthy lifestyles, making individuals more susceptible to viral infections. The market's future looks promising with ongoing research and advancements in treatment methods.

Download PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2023 and 2028
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies